It would seem to me that in the current climate where vaccines are being hailed one minute and dismissed the next that any Covid trial which is under 50% complete would be more more difficult to hail as a breakthrough.
Therefore going to at least 60% tested before the trial could be halted for efficacy would seem better for all parties MSB, FDA, and most importantly the sick.
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-113
-
- There are more pages in this discussion • 280 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.010(1.02%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 95.5¢ | $6.248M | 6.438M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 116040 | 7 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |